Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

IntuitiveFosun Partners with Sinopharm CDMC to Advance Surgical Robotics Adoption in China

Fineline Cube Apr 10, 2026
Company Deals

Gan & Lee Licenses Bonfaglutide to JW Pharma for $81.1M – Expands GLP‑1 Footprint into South Korea

Fineline Cube Apr 9, 2026
Company Deals

Grand Pharma Partners with HKU on Anti‑Infective Drug Discovery – Exclusive License Deal Targets Novel Antibacterial Therapies

Fineline Cube Apr 9, 2026
Company Deals

Wuhan Ammunition Life-tech Files Hong Kong IPO Prospectus, Pioneering Methylation-Based Early Cancer Detection with Liver and Urothelial Cancer Tests

Fineline Cube Apr 8, 2026
Company Deals

Gilead Sciences to Acquire Tubulis for $3.15B Upfront, Adding Next-Generation ADCs TUB-040 and TUB-030 to Oncology Pipeline

Fineline Cube Apr 8, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Duality Biologics’ HER2-Targeted ADC DB-1303 (BNT323) Enters NMPA Review for Metastatic Breast Cancer

Fineline Cube Apr 10, 2026
Company Drug

Haisco Pharma’s HSK42360 Selected for NMPA SPARK Program – First BRAF V600 Inhibitor for Pediatric Glioma in China

Fineline Cube Apr 9, 2026
Company

Apeloa Pharmaceutical Expands Global Footprint with Apeloa Europe GmbH in Germany

Fineline Cube Oct 10, 2023

China-based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has announced...

Company Deals

AbbVie Acquires Mitokinin, Advancing PINK1 Activator for Parkinson’s Disease

Fineline Cube Oct 10, 2023

AbbVie (NYSE: ABBV) has announced the acquisition of US-based biotechnology company Mitokinin, exercising an exclusive...

Company Drug

Shanghai BDgene’s BD112 Earns Orphan Drug Designation from US FDA for Huntington’s Disease

Fineline Cube Oct 10, 2023

Shanghai BDgene Technology Co., Ltd, a specialist in gene therapy, has announced that its drug...

Company

AstraZeneca Alum Yu Yuping Appointed Vice-President at Merck KGaA’s China Unit

Fineline Cube Oct 10, 2023

Yu Yuping, a seasoned professional with a distinguished career at AstraZeneca (AZ, NASDAQ: AZN), has...

Company Deals

AffaMed Technologies Secures Exclusive Rights to SIFI’s Intraocular Lens Products in Greater China

Fineline Cube Oct 10, 2023

AffaMed Technologies, a joint venture between China’s AffaMed Therapeutics and Italy-based SIFI S.p.A., has announced...

Company Deals

Simcere Pharmaceutical Secures Exclusive Rights to AnDiCon’s Anti-Influenza Candidate ADC189

Fineline Cube Oct 10, 2023

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced a strategic collaboration agreement with domestic firm...

Company Drug

J&J’s Janssen Reports Favorable Spravato Data in Late-Stage TRD Trial

Fineline Cube Oct 10, 2023

Johnson & Johnson’s (J&J; NYSE: JNJ) subsidiary, Janssen, has presented tolerability and efficacy data from...

Company Deals

BMS to Acquire Mirati Therapeutics in a $4.8 Billion Deal

Fineline Cube Oct 10, 2023

Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into a definitive merger agreement with US-based oncology...

Company Deals

Canada’s SGC Partners with HitGen to Enhance Drug Discovery Using DEL Technology

Fineline Cube Oct 9, 2023

The Structural Genomics Consortium (SGC) of Canada has announced a strategic partnership with China-based HitGen...

Company Deals

Adlai Nortye Completes Successful IPO on Nasdaq, Raising $57.5 Million

Fineline Cube Oct 9, 2023

Sino-US biotech Adlai Nortye Ltd (NASDAQ: ANL) successfully completed its initial public offering (IPO) on...

Company Drug

Eli Lilly Launches Three New Oncology Programs Targeting KRAS and Nectin-4

Fineline Cube Oct 9, 2023

Eli Lilly (NYSE: LLY) has announced the initiation of three innovative oncology programs focusing on...

Company Drug

FDA Rejects Eli Lilly’s Application for Lebrikizumab in Atopic Dermatitis Treatment

Fineline Cube Oct 9, 2023

The U.S. Food and Drug Administration (FDA) has rejected Eli Lilly’s (NYSE: LLY) application for...

Company Deals

Bayer Partners with Twist Bioscience for Antibody Discovery in Multiple Disease Areas

Fineline Cube Oct 9, 2023

German pharmaceutical giant Bayer (ETR: BAYN) has entered into a strategic partnership with drug discovery...

Policy / Regulatory

Beijing Launches Comprehensive Plan to Eliminate Cervical Cancer by 2030

Fineline Cube Oct 9, 2023

The Beijing Municipal Health Commission, in collaboration with the Beijing Municipal Medical Insurance Bureau and...

Company Deals

ZhenGe Biotech Partners with Glyco-Therapy to Develop Antibody Drug Conjugate Platform

Fineline Cube Oct 9, 2023

China-based Contract Development and Manufacturing Organization (CDMO) ZhenGe Biotech has announced a strategic partnership with...

Company Deals

Alphamab Oncology Enters Licensing Agreement with Grand Life Sciences for KN057 in Greater China

Fineline Cube Oct 9, 2023

China-based Alphamab Oncology (HKG: 9966) has announced a licensing agreement with fellow Chinese firm Grand...

Company Deals

Chongqing Zhifei Partners with GSK for Shingrix Distribution in China

Fineline Cube Oct 9, 2023

China-based Chongqing Zhifei Biological Co., Ltd. (SHE: 300122) has entered into a sole distribution and...

Company Deals

Mabwell Bioscience Enters Licensing Agreement with Laboratorios Legrand for Biosimilars in Colombia and Ecuador

Fineline Cube Oct 9, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has announced a strategic licensing agreement with...

Company Drug

Innovent Biologics Doses First Patient in Phase 3 Study of IBI302 for Neovascular AMD

Fineline Cube Oct 9, 2023

China-based Innovent Biologics, Inc. (HKG: 1801) has announced that the first patient with neovascular age-related...

Policy / Regulatory

NHSA Issues Guidelines to Strengthen Medical Insurance Payment Management

Fineline Cube Oct 9, 2023

The National Healthcare Security Administration (NHSA) has released a set of guiding opinions aimed at...

Posts pagination

1 … 445 446 447 … 648

Recent updates

  • Duality Biologics’ HER2-Targeted ADC DB-1303 (BNT323) Enters NMPA Review for Metastatic Breast Cancer
  • IntuitiveFosun Partners with Sinopharm CDMC to Advance Surgical Robotics Adoption in China
  • Haisco Pharma’s HSK42360 Selected for NMPA SPARK Program – First BRAF V600 Inhibitor for Pediatric Glioma in China
  • Luye Pharma Doses First Patient in Phase II Study of LY03020 – World’s First Dual‑Target TAAR1/5‑HT2CR Agonist for Schizophrenia
  • Sino Biopharm Wins FDA Approval for Pan‑KRAS Inhibitor TQB3205 – First‑in‑Human Trial in Advanced Malignancies
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Duality Biologics’ HER2-Targeted ADC DB-1303 (BNT323) Enters NMPA Review for Metastatic Breast Cancer

Company Deals

IntuitiveFosun Partners with Sinopharm CDMC to Advance Surgical Robotics Adoption in China

Company Drug

Haisco Pharma’s HSK42360 Selected for NMPA SPARK Program – First BRAF V600 Inhibitor for Pediatric Glioma in China

Company Drug

Luye Pharma Doses First Patient in Phase II Study of LY03020 – World’s First Dual‑Target TAAR1/5‑HT2CR Agonist for Schizophrenia

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.